Information Provided By: 
Fly News Breaks for January 28, 2020
XLRN
Jan 28, 2020 | 07:48 EDT
Oppenheimer analyst Leland Gershell raised his price target for Acceleron to $79 from $57 saying that a "strong" top-line showing by sotatercept in the 106-patient PULSAR trial in PAH comes as upside surprise, as he believes the majority of Street models reflected little, if any, value for this commercial opportunity. Based on the report, the analyst foresees $800M-plus peak sales for this wholly-owned asset. He reiterates an Outperform rating on the shares.
News For XLRN From the Last 2 Days
There are no results for your query XLRN
